- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Cevostamab Plus Pomalidomide/Dexamethasone Is Safe, Active in R/R Myeloma
September 17th 2025, 8:50pm
International Myeloma Society Annual Meeting
The combination of cevostamab, pomalidomide, and dexamethasone was deemed safe with early efficacy signals in relapsed/refractory multiple myeloma.
Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, Newly Diagnosed Myeloma
September 17th 2025, 7:08pm
International Myeloma Society Annual Meeting
Early and promising efficacy was shown with elranatamab added to daratumumab/lenalidomide in transplant-ineligible, newly diagnosed multiple myeloma.
Tarlatamab Plus Anti–PD-L1 as Frontline Maintenance Shows Unprecedented OS in ES-SCLC
September 15th 2025, 12:00pm
IASLC World Conference on Lung Cancer
Tarlatamab plus anti–PD-L1 as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.
Tarlatamab Plus Anti–PD-L1 Therapy as Frontline Maintenance Shows Unprecedented OS in ES-SCLC
September 15th 2025, 12:00pm
IASLC World Conference on Lung Cancer
Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.
OncLive Fellows Forum Spotlights New Data for Tarlatamab in SCLC and PRO Results in Hospitalized Patients
September 13th 2025, 10:00am
Kelsey Pan, MD, MPH, discusses notable presentations from an OncLive Fellows Forum on Thoracic Oncology.
Experts Highlight Key Topics to Watch at the 22nd International Myeloma Society Annual Meeting
September 11th 2025, 2:00pm
International Myeloma Society Annual Meeting
Experts preview abstracts being presented at IMS, highlighting the role of MRD, bispecific antibodies, and other strategies to refine myeloma management.
FLAURA-2 and HARMONi Trial Readouts Reinforce Importance of ‘Divide and Conquer’ Approach to Lung Cancer Care at WCLC 2025
September 11th 2025, 12:00pm
IASLC World Conference on Lung Cancer
Experts reflect on pivotal data, emerging agents, and highly anticipated trends in lung cancer during the IASLC 2025 World Conference on Lung Cancer.
Dr Schlechter on the Safety of Botensilimab Plus Balstilimab in Pretreated MSS CRC
September 10th 2025, 10:24pm
ESMO Gastrointestinal Cancers Congress
Benjamin L. Schlechter, MD, discusses safety with botensilimab plus balstilimab in MSS CRC.
Lutetium Lu 177 Dotatate Yields Partial Responses in Metastatic Bronchopulmonary Neuroendocrine Tumors
September 10th 2025, 7:00pm
IASLC World Conference on Lung Cancer
Real-world data showed that lutetium Lu 177 dotatate led to partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors.
Navigating Novel IO Regimens and ADCs in Lung Cancer With Drs Rodriguez, Olazagasti, and Roy
September 10th 2025, 4:30pm
OncLive News Network: On Location at WCLC 2025
Estelamari Rodriguez, MD, MPH, Coral Olazagasti, MD, and Tina Roy, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
SOHO Spotlight: Hematologists Share Practice-Informing Insights From the 2025 Annual Meeting
September 10th 2025, 2:00pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.
Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC
September 10th 2025, 1:00pm
IASLC World Conference on Lung Cancer
Repotrectinib elicited durable responses, including intracranial responses, in TKI-naive and -pretreated patients with NSCLC.
Cemiplimab Plus Chemotherapy Provides Long-Term Survival Benefit in Advanced NSCLC
September 10th 2025, 11:00am
IASLC World Conference on Lung Cancer
Five-year data show cemiplimab plus chemotherapy delivers durable OS, ORR, and DOR benefits in advanced NSCLC.
Dr Xia on the Differences Between ctDNA Monitoring Strategies in MET Exon 14–Mutant NSCLC
September 9th 2025, 8:03pm
IASLC World Conference on Lung Cancer
Yang Xia, MD, PhD, discusses the use of different ctDNA monitoring to detect resistance and predict outcomes in NSCLC with MET exon 14 skipping mutations.
Dr Lim on the Potential Role for Subcutaneous Amivantamab in EGFR-Mutant NSCLC
September 9th 2025, 7:53pm
IASLC World Conference on Lung Cancer
Sun-Min Lim, MD, PhD, discusses the potential adoption of first-line subcutaneous amivantamab plus chemotherapy in EGFR-mutant NSCLC.
Firmonertinib Demonstrates Antitumor Activity, CNS Responses in EGFR PACC–Mutated NSCLC
September 9th 2025, 6:32pm
IASLC World Conference on Lung Cancer
Firmonertinib was active and safe at both the 160-mg and 240-mg dose levels across a broad range of patients with NSCLC harboring EGFR PACC mutations.
Double-Dose Firmonertinib Showing Promising Activity in First-Line EGFR L858R–Mutated NSCLC
September 9th 2025, 4:54pm
IASLC World Conference on Lung Cancer
Firmonertinib led to responses with a tolerable safety profile in frontline EGFR L858R–mutated NSCLC.
Reviewing Key Data in Resectable and ROS1+ NSCLC With Drs Florez and Sabari
September 9th 2025, 4:15pm
OncLive News Network: On Location at WCLC 2025
Narjust Florez, MD, and Joshua K. Sabari, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
Pooled Analysis Shows Manageable Safety Profile With Tepotinib in MET Exon 14+ NSCLC
September 9th 2025, 3:30pm
IASLC World Conference on Lung Cancer
Tepotinib treatment was characterized by frequent but manageable TRAEs in MET exon 14–positive NSCLC, with peripheral edema as the most common toxicity.
SKYSCRAPER-05 Data Confirm Surgical Feasibility After Perioperative Tiragolumab Combo in NSCLC
September 9th 2025, 12:00pm
IASLC World Conference on Lung Cancer
The SKYSCRAPER-05 trial shed light on the use of perioperative tiragolumab plus atezolizumab with or without chemotherapy in NSCLC.